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Background: A common and potentially life-threatening complication of the treatment of childhood cancer is
infection, which frequently presents as fever with neutropenia. The standard management of such episodes is the
extensive use of intravenous antibiotics, and though it produces excellent survival rates of over 95%, it greatly
inconveniences the three-fourths of patients who do not require such aggressive treatment. There have been a
number of studies which have aimed to develop risk prediction models to stratify treatment. Individual participant
data (IPD) meta-analysis in therapeutic studies has been developed to improve the precision and reliability of
answers to questions of treatment effect and recently have been suggested to be used to answer questions
regarding prognosis and diagnosis to gain greater power from the frequently small individual studies.
Design: In the IPD protocol, we will collect and synthesise IPD from multiple studies and examine the outcomes
of episodes of febrile neutropenia as a consequence of their treatment for malignant disease. We will develop and
evaluate a risk stratification model using hierarchical regression models to stratify patients by their risk of
experiencing adverse outcomes during an episode. We will also explore specific practical and methodological
issues regarding adaptation of established techniques of IPD meta-analysis of interventions for use in synthesising
evidence derived from IPD from multiple studies for use in predictive modelling contexts.
Discussion: Our aim in using this model is to define a group of individuals at low risk for febrile neutropenia who
might be treated with reduced intensity or duration of antibiotic therapy and so reduce the inconvenience and
cost of these episodes, as well as to define a group of patients at very high risk of complications who could be
subject to more intensive therapies. The project will also help develop methods of IPD predictive modelling for use
in future studies of risk prediction.
Keywords: individual participant data meta-analysis, predictive modelling, paediatric oncology, febrile neutropenia,
collaborative studies
Background
Children undergoing treatment for malignancy have an
excellent chance of survival, with overall rates approach-
ing 75% [1]. In most cases, children who die following
treatment for cancer do so as a result of their disease,
but despite huge improvements in supportive care,
around 16% of deaths within 5 years of diagnosis are
due to the complications of therapy [2,3]. One such life-
threatening complication in immunocompromised chil-
dren remains infection, which frequently manifests as
the occurrence of fever with neutropenia [4].
In adopting a policy of aggressive inpatient intravenous
antibiotic use in such episodes, the mortality rate related
to these episodes has improved dramatically (from 30%
in the 1970s to 1% in the late 1990s) [4]. Intensive care
management is required in less than 5% of cases [5-7],
although a substantial proportion of children have com-
plications which require specialised care [7]. There
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sibly two-thirds or more, among patients in whom no
significant infection is identified and in whom this
aggressive management strategy is likely to be excessive
[7].
To better inform the clinical management of children
with cancer and FNP, there is increasing interest in
using risk prediction models (also known as ‘prognostic
models’) and clinical decision rules (CDRs) [8-10]. Risk
prediction models utilise multiple prognostic factors in
combination to predict the risk of a future health out-
come for an individual on the basis of their set of prog-
nostic factor values. A CDR recommends a particular
clinical action (or inaction) for an individual on the
basis of the prediction (for example, the predicted prob-
ability, or ‘risk score’) derived from the model.
A robust risk prediction model which identifies those
children at very low risk of having a significant infection
could result in reduced intensity and/or duration of anti-
biotic therapy in the hospital. It could also form the basis
of a randomised controlled trial (RCT) of alternative
management approaches (for example, ambulatory oral
antibiotics vs inpatient intravenous antibiotics) and
w o u l db et h ei d e a lw a yo fi n f o r m i n gt h es a m p l es i z e
required by reliably predicting the proportion of events
expected in a low-risk group. This would lead to reduced
costs for the healthcare system and the patient and family
[11], as well as potentially a better quality of life for all
affected. At present, there are many differing policies for
the management of FNP in practice [12,13] but a lack of
agreement about how and which CDRs, if any, are used.
Assessment of the risk of adverse outcome of each epi-
sode of FNP has been undertaken by many different
groups, with many of them creating a CDR which aims to
allow clinicians to accurately judge risk and treat patients
appropriately. However, none of these analyses have
resulted in a widely used risk stratification model, and cur-
rent practice is variable, both in the United Kingdom [12]
and internationally [13-15]. Some centres use a risk-strati-
fied, reduced-intensity approach, and others treat all chil-
dren aggressively. The essential problems with research in
this area are common across much of paediatric practice:
those of rare conditions with small numbers of cases and
limited collaboration in primary studies. The modelling
studies that have been done have incorporated different
clinical features and outcomes and have used different
methodologies, and it is therefore difficult to draw mean-
ingful conclusions from this body of evidence. Calls for
collaborative trials [16-18] have led to little progress.
This setting provides an ideal opportunity to under-
take a collaborative, pooled analysis of the existing data
sets in the form of an individual participant data (IPD)
meta-analysis. In this effort, we will collect and reanalyse
the original study data, which will permit reanalysis of
the same clinical features across studies using a consis-
tent approach and provide sufficient numbers to draw
more robust and reliable conclusions. The findings of
this work should therefore more robustly inform prac-
tice and future therapeutic RCTs. The analysis can be
approached from three methodological directions: test-
i n ge x i s t i n gC D R sf o rt h e i ra b i l i t yt o‘diagnose’ adverse
outcomes, assessing the added value of individual prog-
nostic factors and building a more accurate predictive
rule containing a parsimonious set of prognostic factors.
Systematic reviews of existing knowledge
In preparation for this project, two systematic reviews
were undertaken to assess the prior knowledge of the
discriminatory ability of CDRs [19] and inflammatory
serum markers (R Phillips, R Wade, T Lehrnbecher, LS
Stewart, A Sutton) in children and young people with
FNP. The systematic review of CDRs initially identified
2,057 potential studies and finally included 24, of which
2 1h a dd a t ai nau s a b l ef o r m a t .I ts h o w e dt h a tt w o
groups of studies have been undertaken to risk-stratify
children who present with FNP. Researchers in the first
group of studies examined the use of clinical examina-
tions to predict radiographic pneumonia (4 studies) [20],
and investigators in the second group examined more
general infectious complications (20 studies) [19].
Among the studies in which general infectious compli-
cations were examined, 16 separate models were pro-
duced and contained 9 data sets used to validate
previously derived models. The researchers studied a
variety of outcomes with individual differences in defini-
tions, but covered five main categories: death, critical
care requirement, serious medical complications, signifi-
cant bacterial infections and bacteraemia.
Only one rule could reasonably be assessed across
multiple data sets: that of absolute monocyte count and
temperature criteria proposed by Rackoff et al. [21] to
exclude bacteraemia. The most appropriate meta-analy-
sis of the rule’s effectiveness led to estimates of moder-
ate discriminatory ability, with the average probability of
bacteraemia in the groups being low risk = 6% (95% CrI
= 1% to 34%), middle-level risk = 18% (CrI = 3% to
37%) and high risk = 49% (95% CrI = 6 to 84%).
Of the other rules, the model of Santolaya et al. [22]
showed a good ability to differentiate between low- and
high-risk groups when a wider definition of ‘serious
infection’ was used, with average predictive ability esti-
mated as low risk = 13% (95% CI = 9% to 18%) and
high risk = 72% (95% CI = 68% to 75%). The rule has
been developed and tested in Chile and may be of lim-
ited applicability in Western Europe and North America
[23]. Other rules show promise and have clinical physio-
logical similarities, but have not undergone extensive
testing.
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markers of inflammation and infection in children pre-
senting with FNP included 27 studies reporting over 13
different markers derived from an initial screen of 375
studies. The studies included had similar methodological
challenges as well as problems with reporting and analy-
sis. Many failed to assess whether the marker had any
supplementary value over and above the simple admis-
sion data collected by the clinicians at every encounter:
age, malignancy, temperature, age-corrected vital statis-
tics and blood count.
To interpret the information on serum markers in a
clinically meaningful way, we had to allow for the
marked heterogeneity of the results. The quantitative
pooling and a qualitative summary of the results sug-
gested that procalcitonin might be a better discrimina-
tory marker than C-reactive protein (CRP) and that IL-6
had a very good ability to predict documented infection.
Overall the findings were uncertain and unstable, and
only small amounts of new data may alter them sub-
stantially. Data for the other markers were too sparse to
reasonably be interpreted, although IL-8 had significant
potential value.
T h e s er e v i e w sh a v eaw i d er a n g eo fr u l e sf o rt h ep r e -
diction of poor outcomes during episodes of FNP in
children and the use of a variety of individual serum
markers to predict outcome. None of the rules found
has yet been subjected to the extensive geographical and
temporal discriminatory validity assessments that mark
the highest quality CDR. Many potential difficulties with
different outcomes, variable selection and model-build-
i n gh a v eb e e ni d e n t i f i e d .T h ed a t ao ns e r u mm a r k e r s
were extremely heterogeneous, and only tentative con-
clusions could be drawn.
The problems identified are inherent in the attempt to
undertake meta-analyses of aggregate data. The limita-
tions of the reporting in published studies mean we do
not have access to the exact data distribution or the full
range of univariable estimates of predictive power.
These issues could be addressed by attempting to collect
more detailed summary data from the authors of the
original studies, but this would not allow cross-study
validation of different rules or attempts at alternative
rule-building. To meet these challenges and to maximise
the value of the information already collected by these
groups and in other cohorts of children with FNP, an
IPD meta-analysis will enable us to develop and test
new and existing prediction models. This will provide a
firmer basis for stratified treatment trials in this com-
mon and occasionally fatal complication of therapy.
Rationale for an individual participant data analysis
Individual patient data pooled analysis in therapeutic
studies have been developed for two decades to improve
the precision and reliability of answers to questions
regarding treatment [24,25]. It has more recently been
promoted for the synthesis of diagnostic data [26] and
prognostic information [27] to improve the quality of
answers to important prognostic questions [28] and
matters of diagnostic accuracy [29]. These techniques
have been applied to real-world clinical data sets
[30,31], in which they have clarified existing understand-
ing of particular prognostic variables and enhanced
understanding of how different diagnostic tests can be
used [32].
The key benefits of prognostic IPD analysis generally
can be summarised as follows: (1) Analyses are not
restricted to those of the published results or subgroups;
(2) analytical techniques, inclusion criteria and outcome
definitions can be standardised across studies; (3) larger
numbers of data points allow more powerful statistical
conclusions to be drawn, including checking modelling
assumptions and accounting for missing data at the
individual level; (4) IPD can model data more appropri-
ately, such as by analysing continuous variables on con-
tinuous scales (unlike in many prognostic studies in
which data are reported as categorical variables); (5)
analysis can account for clustering (for example, of
patients within studies) and correlated information (for
example, multiple events per individual); (6) multivariate
models can be created across different healthcare set-
tings; (7) data can be reviewed for completeness and
accuracy; and (8) the analysis can provide extensive
internal cross-validation to guard against data-driven
exaggerations of predictive power.
In the Predicting Infectious Complications of Neutro-
penic sepsis In Children with Cancer (PICNICC) study,
the collection and analysis of IPD will provide specific
benefits that overcome many of the problems found in
the aggregate data meta-analysis. Many of the benefits
of IPD analysis are technical, being related to the statis-
tical methods underlying the meta-analysis and the
building of predictive models. Although at first sight the
failure to address the problems inherent in statistical
interpretation may seem to be clinically irrelevant, it has
clear and real clinical implications [33]. Other benefits
are more obviously clinical; for example, the collection
of the different data sets will enable us to clarify and
harmonise the different outcomes collected.
One of the primary ‘statistical’ benefits will be the use
of firmly prespecified potential predictor variables built
upon the experience of the PICNICC Collaborative and
the systematic reviews. This will guard against the devel-
opment of purely data-driven analyses, which have a
tendency to overestimate any predictive value [28].
In the reviews, we found the studies designed to build
a CDR used a large number of variables (median = 13,
range = 2 to 39) and had a small number of events
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studies having fewer than 10 events per variable under
consideration and no study having more than 14 events
per variable. These low event-per-variable ratios render
predictive conclusions drawn from the studies unstable
and estimates of predictive power overly optimistic [34].
IPD will allow us to consolidate the information and
increase greatly the number of events studied from the
same number of predictive variables.
The raw data will also allow a detailed analysis of the
clustering of events (multiple episodes per patient) and
variation at the level of the individual patient. This issue
is significant when assessing the problems identified in
the aggregate data reviews. Multiple episodes in indivi-
dual patients were treated primarily as if they came
from dissimilar individuals in the 20 CDR and 24 serum
marker studies. Four papers explicitly described no
adjustment [22,35-37], with 12 undertaking some
attempt at assessment. Secondary analysis was per-
formed to assess ‘first included case’ versus ‘all episodes’
and ‘no significant differences’ in three studies
[22,38,39] and in nine others in which more advanced
statistical modelling was used [6,21,40-46]. In 28 studies,
the assessment was unclear.
The functional form of the data regarding ap r i o r i
nonlinear fractional polynomial relationships can be
assessed in detail. In no study assessed were clear
attempts made to fit nonlinear forms to the data. This is
unsurprising, as the development of practical techniques
to undertake this effort is very recent [47].
Modern statistical developments in the handling of
missing data may enhance the information already
acquired. Again, very little information on the assess-
ment and management of missing data was available
from the reviews (five CDR studies [21,38,39,42,44] and
two serum marker studies [48,49]). Very recent publica-
tions of studies in which simulation [50] and surveying
p r a c t i c e[ 5 1 ]w e r eu s e dp r o d u c e dw o r k a b l eg u i d e l i n e s
for the use of imputation techniques to maximise the
value of the data collected. IPD will allow us not only to
test existing rules and combine data derived from
attempts to examine the rules but also, potentially, to
develop a more robust rule for future use worldwide.
Parent and/or caregiver involvement
The development of shared research initiatives involving
patients, clinicians and researchers has been a notable
change in the practice of clinical research over the past
decade [52]. It remains surprising to many researchers,
clinicians and patients when they learn that their views
are often strikingly different from each others’ [53]. A
systematic review of studies of the process of research
planning and priority setting undertaken by the James
Lind Alliance [52] demonstrated that the involvement of
patients and parents as well as other caregivers was
extremely infrequent.
The PICNICC group has sought to involve parents
early in the treatment process. Discussions of the nature
of their engagement in the process have so far high-
lighted that the representatives involved have not wished
to be actively involved in the process of reviewing, but
to be included in discussions about the nature of, the
adverse effects of FNP and that they have been willing
to provide their own nonmedical expertise in advancing
the project.
The discussion of the nature and extent of patient and
caregiver involvement in the PICNICC group will con-
tinue as the project develops. Possible opportunities for
further involvement include writing commentaries on
the study for patients and their families, providing
alterative views on ethical questions, making choices
regarding risk thresholds and considering how uncer-




A primary aim of the project is to undertake an IPD
pooled analysis to quantify the risk of adverse clinical
outcomes according to clinical variables in children and
young people undergoing treatment for malignant dis-
ease who present with an episode of FNP; that is, to
identify which variables are prognostic and which have
the most independent prognostic importance. Another
primary aim is to develop and validate a new risk pre-
diction model containing multiple prognostic factors in
combination.
Secondary
The secondary aim of this project is to develop and
explore practical and methodological issues surrounding
the use of pooled IPD analysis in the development of
predictive models.
Inclusion and exclusion criteria
Studies will be considered for inclusion in the IPD
meta-analysis if they are cohort studies of children and
young people presenting with FNP and/or with either
prospective or retrospective data collection, including
RCT data; if they provide data for all ‘essential’ predic-
tive variables in more than 50% of included episodes
(see ‘Core data set and variables’ section); and if they
provide details of two or more study-defined outcomes
in more than 90% of individual episodes of FNP.
Studies will be excluded if they are case series (for
example, studies of only ‘Gram-negative bacteraemias’)
and if they did not record data on all ‘essential’ predic-
tive variables or cannot provide sufficient outcome data.
Studies will be included if they focus on the collection
of data from children and young people (between 0 and
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studies of young people up to the age of 24 years is to
address a paucity of research on individuals in the
‘young adult’ age range [54]. Data from individual
patients ages 25 years and older will be excluded from
this analysis. The median age of inclusion in the ‘chil-
dren’s’ cohorts examined in our reviews was about 7
years old (ranging from 1 month to 23 years), and the
‘adult’ study from the Multinational Association for Sup-
portive Care in Cancer group [55,56] has a median age
of 52 years (range, 16 to 91 years old).
Identification of potential studies
The initial identification of studies has been through
extensive literature searches undertaken as part of the
systematic reviews reported briefly in the Additional
material at the end of the protocol (see Appendix 1 in
Additional file 1 for a list of studies).
The following databases were searched by two inde-
pendent reviewers to identify potential collaborators:
MEDLINE, MEDLINE in-process and other nonindexed
citations, Embase, Cumulative Index to Nursing and
Allied Health Literature, Cochrane Database of Systema-
tic Reviews, Database of Abstracts of Reviews of Effects,
Health Technology Assessment Database, Cochrane
Central Register of Controlled Trials, Thomson Reuters
Conference Proceedings Citation Index-Science and Lit-
eratura Latinoamericana y del Caribe en Ciencias de la
Salud. The reference lists of relevant systematic reviews
and included articles were reviewed for further relevant
studies. Published and unpublished studies were sought,
and no language restrictions were applied. Non-English-
language studies were translated into English. (See
Appendix 2 in Additional file 2 for a sample search that
we conducted.)
Further analysis of the initial literature searches will be
undertaken to identify any published cohorts of FNP
patients that may have been excluded from the reviews
because a CDR or serum marker was not tested, yet
could provide the information essential to being
included in the IPD study. In addition to this, open calls
for participation have been made via the International
Society for Paediatric Oncology Supportive Care Group,
the University of York Centre for Reviews and Dissemi-
nation website (http://www.york.ac.uk/inst/crd/projects/
picnicc_patient.htm), presentations at relevant UK and
international conferences, and via the Oncopedia web
community of paediatric oncologists (https://www.cur-
e4kids.org/ums/home/index.php?location=%2Fums%
2Foncopedia%2F).
Core data set and variables
This IPD meta-analysis will develop a risk stratification
model to predict which children and young people have
a low risk of adverse outcomes during an episode of
FNP. The predictor variables and adverse outcomes
sought have been based on our systematic reviews of
aggregate data, in which exploratory analysis showed
that age, malignant disease state, clinical assessment of
circulatory and respiratory compromise, higher body
temperatures and bone marrow suppression had expla-
natory value and reflected clinical experience of the pae-
diatric oncologists.
The following predictor variables are divided into
‘essential’ and ‘desirable’ items and can be categorised as
(1) patient-related, episode-related clinical variables and
(2) patient-related, episode-related laboratory variables:
1. Age
2. Underlying tumour type
3. Marrow involvement and/or remission status
4. Chemotherapy type and time elapsed since last
cycle
5. Presence of central venous line
6. Inpatient or outpatient at onset of episode
7. Maximum temperature
8. Antibiotic therapy used
9. Respiratory rate (or compromise)
10. Circulatory parameters (or compromise)
11. Severe mucositis
12. Global assessment of illness severity
13. Haemoglobin
14. Platelet count











3. Need for moderate organ support (fluid bolus,
oxygen)
4. Clinically documented infections
5. Microbiologically documented infections
Two or more of these outcome measures should be
provided for more than 90% of episodes.
If available, we will also collect data on the following:
1. Duration of fever
2. Duration of admission
An example of the initial survey of data available from
collaborators is provided in Appendix 3 in Additional
file 3. An a priori mapping schema linking microbiologi-
cal and clinical outcome variables into a unified descrip-
tion of ‘severe’ and ‘nonsevere’ infections has been
developed to assist with unifying outcome definitions.
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Anonymised deidentified data
Data sets should be anonymised (that is, have all directly
identifiable material removed, such as name, address,
postal code, record number). A patient identification
number should be provided to facilitate communication
and data queries. For the purposes of this report, the
age of the patient (an indirect identifier) is essential and
should be provided [57].
Data format
The data will be accepted by the PICNICC Collaborative
in any electronic format, but ideally a ‘flat’ spreadsheet
format (such as Microsoft Excel; Microsoft Corp, Red-
mond, WA, USA) will be most useful, with one episode
per row and variables listed in columns. Each patient
should be assigned an in-cohort unique identifier (such
a sas i m p l en u m b e r1 ,2. . .n) to highlight repeated epi-
sodes in the same patient. A suggestion for coding the
variables is provided in Appendix 4 in Additional file 4
and a sample flat file is available on request.
Transfer of data
The data should be transferred to a secure password-
protected web server or by pretty good privacy-
encrypted email. This permits a secure and identifiable
connection to the University of York servers and mini-
mises the possibility of data loss.
Data checking
Simple checks of data integrity will be undertaken prior
to analysis. These checks will include sense checking of
data (for example, impossibly low presenting tempera-
tures, such as less than 30°C or for second episodes of
FNP where the outcome of the first was death), clarify-
ing missing data (that is, ensuring missing data is
recorded as ‘missing’ rather than ‘zero’) and calculating
simple descriptive statistics of ‘essential’ elements to
assess for ‘outlier’ studies (for example, age, sex, number
of episodes per person). Any problems or inconsisten-
cies flagged during these procedures will be discussed
with the individual responsible for each study and
amended as appropriate by consensus.
Ethical and regulatory considerations
This IPD protocol has been approved in the United
Kingdom by the University of York Health Services
Research Ethics and Research Governance Committee.
Each clinician member of the PICNICC Collaborative is
advised to seek country-specif i ca d v i c er e g a r d i n gt h e
regulations which apply to data shared in this study.
Plan of investigation
Method of analysis
The primary method of analysis for the PICNICC study
will be the use of multivariable logistic regression mod-
elling. There are a series of different analytical
techniques that can be used to produce rules, including
multivariable regression analysis, classification and
regression tree (CART) models, discriminant analysis
and neural networks. There is no clear evidence that
one method is superior to any other [58], and, as multi-
variable logistic models have the widest clinical under-
standing and applicability, this method has been
selected.
In the primary analysis, data used will be from the
first recorded episode for each patient to predict an
absence of adverse outcomes due to the individual epi-
sode (that is, death, intensive care requirement, medical
complication, bacteraemia or other significant bacterial
infection). Following the primary analysis, outcome data
and predictor variables from subsequent episodes will be
analysed to assess the independence or otherwise of
these data, and this information will also be included
using an appropriate model.
Prospective and retrospective cohorts will be consid-
ered separately in the initial analyses on the basis of the
hypothesis that there will be a clinically important dif-
ference between the two types of studies. If no differ-
ence is found, then the data set will be examined as a
whole. The prognostic importance of individual vari-
ables, both unadjusted and adjusted for other variables
(the latter to summarise independent prognostic value),
will be summarised for each study.
Assessment of study and data quality
There is very little advice in the literature for assessing
the quality of prognostic studies. Altman and Lyman
presented suitable criteria that those initiating a primary
prognostic study should consider [59], and they sug-
gested that every effort should be made to limit poten-
tial biases and to emulate the design standards of a
clinical trial. Ideally, the data should be collected pro-
spectively, with little missing data for predictors or out-
comes and with predefined hypothesises. We will use
these guidelines and those published by Hayden et al.
[60] to help inform the quality of the IPD obtained. For
example, an assessment will be made of the proportion
of missing data and the completeness of follow-up. The
influence of any studies considered problematic (for
example, those with large amounts of missing data or a
great deal of incomplete follow-up) on the prediction
model will then be considered, resulting in either their
exclusion or in sensitivity analyses comparing model
estimates when they are included or excluded.
Model development
The model will initially incorporate the simplest predic-
tor variables (malignant diagnosis, age, time since che-
motherapy, and maximum recorded temperature) before
standard additional variables (such as clinical
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tus, white blood cell counts or other haematological
parameters) are added. Further specialist tests (for
example, CRP and IL-6 levels) will be added. The type
of antibiotic therapy used will always be incorporated
into the model as a categorical variable. Potential
sources of heterogeneity (for example, in effects of parti-
cular variables across studies) will be incorporated as
random effects as appropriate. The models will be
assessed for improvement in fit by using an information
criterion (for example, Akaike’s information criterion)
with a P-value of < 0.15 used for inclusion. We will use
a 15% rather than a 5% level, as we feel this is more
conservative and will limit the chance of missing impor-
tant covariates. At the stage of deciding our final model,
however, we will check that the model’s predictive accu-
racy (discriminatory ability) is improved by the inclusion
of variables whose significance is between 5% and 15%.
If predictive accuracy is not improved, then these vari-
ables will be removed.
This approach (of adding specialist tests only after
considering the simpler tests) maximises the utility of a
model by ensuring that, if extra tests with their addi-
tional costs are required, they will add considerable pre-
dictive power to existing simpler variables [61]. We will
use bootstrapping and shrinkage to adjust for potential
overoptimism (bias) in parametric estimates and trends.
Continuous candidate variables will be assessed using
the best fitting functional form considering appropriate
transformations or fractional polynomials (also assessed
using an information criterion) as suggested by previous
evidence. Missing data will be examined to define the
nature of the ‘missingness’. If they are missing at ran-
dom, then multiple imputation techniques will be used
to address these gaps utilising all the other available
data [50,51]. The results of these analyses will be com-
pared with a complete case analysis. We will conduct an
analysis comparing the new model that we develop with
other validated models, for example, that of Santolaya et
al. [62]. This will provide an opportunity to test these
CDRs against data from other geographical areas.
We acknowledge that there may be unforeseen chal-
lenges caused by the variations in the data formats avail-
able from the different studies. Therefore, we
acknowledge that establishing the definitive analysis
plan will be an iterative process and may even demand
novel methodological developments (see ‘Further
research opportunities arising from PICNICC’ section).
Assessing model performance
An important goal of a prediction model is to classify
patients into risk groups. The developed model will pro-
duce a risk score for each individual that is based on
the patient’s own predictor values. We will then use a
cutoff value to decide when a risk score is high (such
that we predict an adverse outcome) and when it is low
(such that we predict a good outcome); this will be our
CDR. The calibration of the model will be assessed by
classifying children into deciles ordered by predicted
risk and considering the agreement between the mean
predicted risk and the observed events in each decile.
The derived CDR will be cross-validated by comparing
the classification of each patient with his or her actual
outcome, thus allowing an estimate of the sensitivity
and specificity of the prediction model. Next, by varying
t h ec h o s e nc u t o f fl e v e l ,w ew i l lb ea b l et op r o d u c ea
receiver operating characteristic curve (ROC) summaris-
ing the sensitivity and specificity of the predictive rule
across the range of cutoffs. The overall discriminatory
ability will be summarised as the area under the ROC
(AUC ROC) with the 95% confidence interval. The most
suitable cutoff level can then also be detected.
Each predictive model will be tested by checking how
it performs against the data from all but one of the stu-
dies in turn (cross-validation of intrinsic prognostic per-
formance) [63] and by using the bootstrap procedure
[64]. This will adjust for overoptimism in the estimation
of model performance due to validation in the same
data set that was used to develop the model itself.
The improvement in model performance by adding
prognostic factors will be assessed by net reclassification
improvement. By analysing the difference among the
prognostic factors, a shrinkage factor will be calculated
and the model will be corrected by this shrinkage factor.
Note also that clustering of patients within studies will
be accounted for in the model framework.
Validation in new data
We will compare the predicted and observed event rates
to assess calibration (as described above) and the AUC
ROC to assess discriminatory ability. If new data
become available after the formation of the PICNICC
Collaborative, they will provide an excellent test bed for
the newly proposed model. Such an analysis is outside
the initial scope of this project. We will update the
model if it shows poor performance to adjust it to the
new situation by recalibration or revision methods,
depending on discrimination performance. Simple diag-
nostic test accuracy measures (such as positive and
negative predictive values) will be computed for a
hypothetical population (with its particular incidence
rates) to aid clinical interpretation of the study results
that define a low-risk group.
Assessment of publication bias
We do not believe that publication bias will affect the
data we obtain. We have sought to retrieve full data
from the studies and so have sidestepped many of the
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different outcome collection and different outcome
assessment methods, but these will not have been biased
by collection and analysis of the predictive data. We
have tried to avoid publication bias by making open
calls for data which has been collected but not yet pub-
lished, and we have probably secured three such data
sets for analysis. This may be too few to undertake a
formal assessment of the difference between the pub-
lished and unpublished sources. We are also using the
data for a purpose different from that used by the origi-
nal data collectors. We are developing a prediction
model, whereas the original researchers are interested
only in the prognostic effect of particular variables.
Furthermore, by obtaining the IPD, we have obtained
outcomes and variables not reported by the original
data collectors in any publication. However, to check
whether our collection of studies may be affected by
publication bias, we will display a funnel plot for each of
the variables included in the final model to see whether
there is asymmetry (that is, potential publication bias).
We will use guidelines for assessing asymmetry recently
published in BMJ [65].
Publication policy
The main results of the meta-analysis will be published
and presented under the PICNICC name, with PIC-
NICC comprising groups supplying data for analysis as
well as its advisory group. Any subsequent technical
papers which describe innovations in the methodologies
used in the meta-analysis will acknowledge the PIC-
NICC Collaborative as the source of the data. The PIC-
NICC Collaborative will disseminate the findings of its
research widely at academic conferences and in journal
publications, on the University of York website and in
lay summaries of the research.
Discussion
Status of the project
Currently, the PICNICC Collaborative has completed
study identification and invitation and has collected data
derived from 23 data sets from 12 countries, including
the Europe-wide European Organisation for Research
and Treatment of Cancer studies. No data analyses have
yet been undertaken. The opportunity to include data
sets for the derivation of a new PICNICC CDR have
now closed, but approaches may be made to the authors
for consideration of inclusion of further data sets in sub-
sequent validation testing or further refinements of the
initiative.
Further research opportunities arising from PICNICC
It is hoped that collaborations developed through the
PICNICC project may also lead to a series of
international studies to improve patients’ experiences
and outcomes with regard to infectious complications in
cancer. One obvious follow-up study might be the use
of the newly derived model in a RCT of alternative
management approaches (for example, ambulatory oral
a n t i b i o t i c sv si n p a t i e n ti n t r avenous antibiotics). Other
studies may include the investigation of genetic poly-
morphisms in determining the outcomes of infectious
episodes; the prediction of specific infections which may
require different management approaches, such as anti-
biotic-resistant bacteraemia; or the prediction of the risk
of an episode of FNP.
The PICNICC Collaborative will provide data that will
prove invaluable in the development of the methodology
of IPD meta-analysis for risk prediction. This develop-
mental work, which will be essential to developing the
best possible model in PICNICC, is outside the core
clinical questions set for the PICNICC Collaborative and
will be undertaken as a series of linked projects. The
problems to be addressed in developing the methodolo-
gies will depend on the nature of the data sets obtained.
They may address issues regarding the analysis of miss-
ing data, the use of different imputation models, the
modelling of multiple-episode data, the relative merits
of prospective and retrospectively collected information,
the use of alternative modelling techniques (such as
CART, structured equation modelling, Bayesian techni-
ques or neural networks), the comparison of episodic
and patient-centred analyses and the use of categorical
outcome variables. A short methodological protocol will
be developed for each methodological investigation prior
to commencement.
Additional material
Additional file 1: Appendix 1: Potential IPD Datasets.
Additional file 2: Appendix 2: Search Strategy.
Additional file 3: Data collection survey.
Additional file 4: Suggested coding structure.
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